e ICUNICAL INVESTIGATIONS

Size: px
Start display at page:

Download "e ICUNICAL INVESTIGATIONS"

Transcription

1 e ICUNICAL INVESTIGATIONS Pulmonary Mycobacterial Infections due to Mycobacterium infracellulare-avium Complex" Clinical Features and Course in 100 Consecutive Cases David Y. Rosenzweig, M.D. One hundred consecutive cases of pulmonary infection due to Mycobacterium intrace"ulare-avium seen dur Ing a 3~-year period qualified for review on the basisof a compatible chest x-ray film, repeated Isolations from eultores of sputum, and follow-up of three to eight yean. ldfections with M intrace"ulare-avium represented 27 percent of all mycobacterial Infections seen during this period, including those due to M tuberculosis. The cases of disease due to M intracellulare-avium were predominantly in men with preexisting pulmonary disease, with a peak Incidence in the sixth decade, but nearly onethird of the eases were in younger penons free of coediting disease. The disease was chronic and indolent in most eases, and only a few showed a progressive coone. A stable course was frequently observed despite prolooged penisten8y positive cultures of sputum. A favorable prognosis was most often found in those with previously treated tuberculosis. Poor prognosis was often due to a serious associated disease, such as cancer, rather than to advancing mycobacterial infection itself. Age, &es, or race was unrelated to prognosis. Conversion to negative status on culture was attained In one-bah of the cases. Those with extensive radiographic Involvement or cavitation were more likely to have treatment fad bac:teriologlcady. No combination of chemotherapy appeared to be particularly effective, includidg the use of Ive or more drugs in eight CMeS demonstrating progressive disease. Surgery, too, was ultimately disappointing In that recurrence appeared in six of 18 carefudy selected cases. pulmonary infections with atypical mycobacteria have gained in prominence in recent years, at a time when infections due to Mycobacterium tuberculosis have declined in number. Each of these infections shares similar clinical and pathologic features, but several important differences relating to host factors, infectiousness, response to therapy, and prognosis exist. This report is a review of the experience with atypical infections due to M infracellulare-aoium complex at the principal tuberculosis facility in a medium-sized metropolitan area. The emphasis is placed on follow-up of cases seen within thepast decade and observed for a minimum of three years. The spectrum of disease appears wider and the prognosis in general better than other recent reports'" would suggest. From the Pulmonary Disease Section, Deparbnent of Medicine, Medical College of Wisconsin, Milwaukee County Medical Complex, Milwaukee. O.Associate Professor of Medicine. Manuscript received August 15, 1977; revision accepted July 25. Reprint requests: Dr. Rosenzweig, 8100 Wen Wl8conrin Aoenue, MilwiJukee CHEST, 75: 2, FEBRUARY, 1979 MATERIALS AND METHODS Consecutive cases were selected from the 3~year period for entry from October 1968 to April They fulfilled the following criteria: (1) lesions on chest x-ray Blm compatible with granulomatous infection; (2) persistent excretion of M intraceuulare-aoium on three or more weekly cultures of sputum, with moderate or numerous colonies; and (3) minimum follow-up of three years, unless death occurred earlier. The sources of these cases were admissions to the hospital and clinic who were referred for newly diagnosed mycobacterial infections or patients at the tuberculosis clinic who had controlled infection with M tubef"culosis and who later developed the problem of persistent excretion of atypical mycobacteria during the period of care at the clinic. Laboratory identification was by standard methods.s and identification of M intraceuulaf"e-avium complex was not further specified. Clinical evaluation was done by retrospective review of records and serial x-ray films. Judgments of radiographic extent and progress were done by the staff of the clinic and my own independent evaluation at a later date. Outcome was assessed by using radiographic and clinical criteria and also by using bacteriologic results, as follows: ( 1) the x-ray film was classified as improved (partial or complete resolution of injiltrates or cavities), stable ( no substantial change during the period of observation), or worse (either brief stepwise advance followed by stable PULMONARY MYCOBACTERIAL INFECnONS 115

2 Table I-NetfJCae. 01 MycobaeteriaJ ln/eeliora duri.. 3~ Year PeriodofSaudy Compared 10 Similar Period Fi"e Year. EarUer January October 1963 to 1968 to Organism July 1966 April 1972 M tuberculosis M intraceuulare-avium * M kansasii Other mycobacteria 4 4 Unspecified or mixed 16 0 *Includes 23 cases withheld from final group under study because of inadequate follow-up. periods of six months or more, or progressive infiltrates and cavities); (2) clinical condition was classified as asymptomatic, improved (improvement or clearing of respiratory symptoms), stable (no loss of weight, fever, or change in respiratory symptoms), or worse (stepwise or progressive systemic or respiratory symptoms); and (3) bacteriologic status was classified as negative status (continuously negative cultures after initial positive stage of variable duration), positive status (continuous or sporadic positive cultures throughout course), or relapse (reemergence of positive cultures after more than six months of negative cultures). Deaths were separated into those primarily due to the infection itseh or those due to other causes. Cases were identified initially from records of the microbiology laboratory. Selections were ended after 100 consecutive cases due to M intraceuulate-aoium qualified for inclusion. Eighteen of these were treated surgically and will be discussed separately in terms of outcome. Twenty-three other cases were excluded because of inadequate follow-up, and five were excluded for lack of a visible radiographic lesion. RESULTS Table 1 shows the bacteriologic distribution of cases of all new mycobacterial disease during the interval in which the 100 cases appeared, as compared to a similar period five years earlier. The decline in cases due to M tuberculosis is matched by a considerable rise in the group with disease due to M intracellulare-avium. Other mycobacterial infections showed a small and steady incidence. The age, sex, and race of the 100 patients with infections due to M intracellulare-aoium are shown in Figure 1. It can be seen that men are predominantly affected, with peak incidence in the sixth decade. The racial distribution is similar to that in the Milwaukee metropolitan area, but blacks appear to be affected at an earlier age. On the basis of older criteria of the American Lung Association," radiologic extent of disease was minimal in 14 cases, moderately advanced in 62 cases, and far advanced in 24 cases. No extrapulmonary involvement, except in adjacent pleura, was recognized in any case. The mean follow-up period was 52 months (range, 36 to 96 months). Other diagnoses were present in these 100 cases of infection due to M intracellulare-aoium in the following numbers: obstructive pulmonary disease, 32 ( five with bullae only); previous tuberculosis (documented M tuberculosis), 28; alcoholism, 20; silicosis, 15; diabetes, ten; atherosclerosis or heart disease, nine; lung cancer, three; other cancer, two; gastrectomy, three; schizophrenia, two; and miscel- 20 (J) W (J) <t u L&.. o a:: w 10 m ~ ::) Z CJ White _ Black 6:::::1 AsianAmerican MEN WOMEN AGE (YEARS) FiGURE 1. Age (by decades), sex, and race of patients with infection due to M intraceuulareavium complex. 118 DAVID Y. ROSENZWEIG CHEST, 75: 2, FEBRUARY, 1979

3 r,,, Table 2-Outeome in 82 NOlUurpeaUy Treated ClUe. of DiM!tJM due 10 M intraeellulare-avium, Compariq Symplomatic and Radio.,.aplaic SItJIw Radiographic Status Worse, Worse, Step- Pro- Data Improved Stable wise gressive Symptoms Asymptomatic throughout Improved Stable Worse 1 5 (5) 3 (1) 7 (2) Outcome Died from mycobacterial disease Died from other causes 0 3 (3) 1 (1) 1 (1) *Numbers withinparenthesesindicatethose withineach group who had advancing co-morbid disease judgedto be separable from status of mycobacterial infection. laneous, five (one each). The common association with obstructive pulmonary disease, silicosis, tumor, or other deleterious local pulmonary host factors has previously been observed.v'" These underlying problems were frequently more important prog- nostically than the mycobacterial infection itself. In other words, the course which some cases pursued could be attributed more to the serious coexisting noninfectious problem than to the chronic infection. This can be illustrated in Table 2, which shows the comparative outcome of the nonsurgically treated cases in terms of symptomatic and radiographic status. In general, these outcomes corresponded closely, and most cases showed a stable or indolent course. Exceptions occurred in eight patients with stable x-ray films, five of whom had advancing symptoms attributable to chronic obstructive pulmonary disease (COPD) and three who died from cancer or cardiovascular disease. Similarly, radiographic improvement was noted in six other patients, all with COPD who had no symptomatic change. While certain underlying diseases conferred a.~ 10 U) <r u LL o 5 ~ I.LJ m ~ ::) Z TIME.YEARS FIGURE 2. Time of infection with M intraceuulare-ooium complex after original tuberculosis was treated and controlled. A Z 100% o iii a: l&j > l&jz ~8 ""u <1_ 50% ~(!) ig :)0 un: l&j t U c:r: CD I ",,~ ",,"".--- Improved 15cases -- Stable 49 cases.. Worse 18cases.",---.","",...~ ","" TIME.YEARS FIGURE 3. Cumulative bacteriologic results related to radiographic status in nonsurgically treated cases. poor prognosis in themselves, the combination of previous tuberculosis and later infection with M intraceuulare-aoium appeared rather benign. These secondary infections occurred from six months to several years after the original tuberculosis was controlled, with little change in incidence with time (Fig 2). Four of these patients showed no new radiographic flndings, while 24 had new but characteristically modest infiltrates or cavities. Only one of these 28 cases with secondary infections developed a progressive problem; the others maintained stab~e radiographic lesions with little or no symptomatic problems. Conversely, a number of infections due to M intraceuulare-aoium, some serious, occurred in otherwise healthy individuals. Twenty-one cases in men and ten in women under the age of 50 years were free of coexisting disease, and five of these 31 pursued a worsening course. Other factors such as race, sex, and age were not found to be related to prognosis. Outcome was also assessed in terms of bacteriologic results. In the medically treated cases, lasting conversion to negative status was reached in 37 (45 percent) of 82 cases. There was considerable relationship between radiographic and bacteriologic results, as shown in Figure 3, which relates cumula~ve attainment of bacteriologic conversion to negative status over time to the radiographic status. This graph also shows that bacteriologic response ~as occasionally delayed well into the second or third year of treatment and that even in the large stable group, persistent excretion of organisms occurred. in half of the cases. The end point of lasting negative bacteriologic status was not always attained. Some cases had intermittent positive cultures for long periods, and these were considered as having positive status continuously. Also, nine cases held negative bacteriologic status for at least six months, only to suffer relapse at a later date, most often one year later, but sometimes as late as three years. Thus, CHEST, 75: 2, FEBRUARY, 1979 PULMONARY MYCOBACTERIAL INFECnONS 117

4 Table 3-Bae'erioloPe Outeome Related 10 Esteral of Di.-.e in Both Medically and SurPeall,. Trealetl CroulM *One relapse with infection due to M kamabii. Table 4--Bae'eriolope Reau'".,11 Set1eralCombirudioM of Chemo'herapy Regimen * Two drugs INH-EMB or INH-PAS Three drugs INH-PAS-SM INH-EMB-SM INH-EMB-RFN Subtotal Four drugs INH-PAS-SM-PZA Five or six drugs Retreatment with assorted five or six drugs Extent of Disease Moderate, Non- Moderate, FarAd- Data Minimal cavitary Cavitary vanced Medical therapy Negative status, lasting Negative status plus late relapse Positive status continuously Total cases Medical-surgical therapy Negative status, lasting 1 2 g. 0 Negative status plus late relapse 2 0 4* 0 Positive status continuously Total cases attaining bacteriologically negative status was advantageous, but failure to do so did not necessarily indicate a worsening course. Bacteriologic response was found to be related to the radiographic extent of disease, as well as the presence of a cavity (Table 3 ). The upper part of Table 3 shows the outcome of the medically treated cases. Failures were concentrated in those with extensive disease, while there was a small number with initial success but late relapse (after six months) in all groups. Treatment consisted of chemotherapy in all cases. Total Cases 2 (25) *INH, isoniazid; EMB, ethambutol; PAS, p-amin08alicylic a~id; ~M, streptomycin; RFN, rifampin; and PZA, pyrasinamide. 8 A Bacteriologic Conversion (percent) 19 8 (42) (39) (48) The standard regimen was three drugs, although regimens of four drugs or two drugs were also used. The last was usually given for minimal extent of infiltrates or in the very elderly. No selection of drugs was based on in vitro testing for sensitivity, as complete resistance to drugs was the rule in each case. Table 4 shows the relative success of various combinations. All were successful in one-thirdto onehalf of the patients receiving the regimen; and none, including those containing rifampin, showed special success. Regimens of five or six drugs for retreatment were offered in eight cases after 4 to 18 months of conventional chemotherapy. These patients all had worsening disease during the initial periodof treatmentand were not considered surgical candidates. While the regimens were reasonably well tolerated, their success was limited. Only two of these eight patients achieved bacteriologically negative status, and these two also showed clinical or radiographic improvement. Resectional surgery was done in 18 patients (16 men and two women). Their median age was 41 years (range, 24 to 56 years). All were carefully selected to have well-localized disease of minimal or moderate extent, and all but two had positive cultures after 6 to 12 months of chemotherapy. Lobectomy was done in each case, and chemotherapy was continued for an additional 6 to 12 months. While the procedures were well tolerated, with a major complication (bronchopleural fistula) in only one case, the long-term results were not uniformly good (Table 3, lower part). Seventeen of 18 patients had negative cultures following surgery, but consistently positive cultures were obtained 6 to 48 months later from five of these 17 cases, and one other developed" infection with M kansasii six years after surgery. In four of these six, radiographic involvement of the contralateral side appeared, and in the other two, ipsilateral new findings appeared. Three of the six developed recurrent respiratory symptoms as well. Because of the small numbers, no clear relation between extent of disease and relapse is seen. Thus, only 11 of 18 cases have achieved lasting stability, despite evidence from bilateral tomograms and at thoracotomy that the disease was confined to one lobe. DISCUSSION While the tuberculosis caseload has declined steadily in the past 10 to 15 years in ourclinic, cases of atypical mycobacterial infection, especially with M intraceuulare-avium, have grown from a trickle to numbers which currently rival those of tuberculosis. Their numbers alone minimize their importance, 118 DAVID Y. ROSENmlG CHEST, 75: 2, FEBRUARY, 1979

5 since the large proportion remaining in a prolonged active state demand a greater share of the clinic's attention than the patients with infection due to M tuberculosis or M kansasii, who nearly always do very well. Although the isolation of these organisms has almost reached a point of banality in the Milwaukee metropolitan area, this has not necessarily been a general trend. The incidence has generally risen slowly in other cities but has remained at or below 10 percent of the incidence of tuberculosis; and in the Midwest in particular, infections with M kansasii have been more common than infections with M intracellulare-aoium. 11 The reasons for this epidemiologic trend are not known. The results of this review support our impression from clinical experience that these infections are indolent and run a benign course in the vast majority of cases. On the other hand, the spectrum is wide, and a few cases pursue a progressive inexorable course. Many have a subtle and stable disease, while others with casual isolates or normal x-ray films defy classification as true disease. These last may represent a saprophytic process or carrier state. The favorable response in those cases with previously treated tuberculosis was unexpected. One explanation could be that tuberculosis confers partial immunity to other mycobacterial infections. Another possibility is that these organisms usually require an impaired host response, and the region "at risk" after tuberculosis is focal and limited, as compared to a more general impairment (as in pneumoconiosis or COPD). Although previously treated tuberculosis was a favorable prognostic indicator in this series, unfavorable clinical indicators could not be identified, except for those diseases which themselves progressed independently of the mycobacterial infection; however, bacteriologic outcome was related to the extent of disease. Patients in this series did not undergo further testing, but we have subsequently examined six recent cases with progressive disease for immunologic deficiency. A battery of cutaneous tests, including purified protein derivative of tuberculin derived from Battey bacilli ( PPD-B), and other tests of both cellular and humoral immunity were performed. Normal findings or only minor deviations were seen in each case, and cutaneous reactivity was also present. Thus, the early identification of progressive infection continues as an elusive problem in our experience. Other recently reported series have indicated a serious prognosis and have advised a vigorous chemotherapeutic and surgical approach. These series differed from the present report in that either CHEST, 75: 2, FEBRUARY, 1979 they dealt with a selected referral population with more extensive and refractory problems,l.!,1 or the methods of analysis, including life table studies,8a failed to properly weigh the confounding roles of coexisting chronic disease which appears to set the stage for this infection. The present report tends to parallel the results of the Veterans Administration Armed Forces Cooperative Study," in which a small fraction of mortality (two of ten deaths) resulted from the infection itself, H one accepts that this report reflects the spectrum of disease seen in the community, then there are important therapeutic implications. H the course is variable but usually benign, if the disease is not contagious, and if the therapeutic effect is meager even with a combined medical-surgical approach, then it is logical to tailor therapy to the individual problem. Vigorous measures with multiple drugs and adjunctive resection should be reserved for those cases demonstrating an unfavorable course. In many cases, observation alone or simple nontoxic drug regimens are appropriate. Perhaps the most difficult problem is identification of the case with a poor prognosis. lleferences 1 Fischer DA, Schaeffer WB, Lester W: Infections with atypical mycobacteria: Five years' experience at the National Jewish Hospital. Am Rev Respir Dis 98:29-34, Lester W, Camwright L, Davidson P, et al: Results of antituberculosis chemotherapy in 130 cases of disease caused by atypical mycobacteria. In Transactions of the 30th Research Conference in Pulmonary Disease, VA Armed Forces, 1971, p 44 3 Yaeger H Jr, Raleigh JW: Pulmonary disease due to Mycobacterium IntraceUultJre. Am Rev Respir Dis 108: , Corpe RF, Liang JL, Sanchez ES: Early and late results with atypical group Hl tuberculosis. Am Rev Respir Dis III:915, Davidson PT: Treatment and longterm followup of patients with atypical mycobacterial infection. Bull Int Union Against Tuberc 51: , Vestal AL: Procedures for the isolation and identification of mycobacteria (DHEW-CDC publication ). Atlanta, Center for Disease Control, Diagnostic standards and classification of Tuberculosis. New York, American Lung Association, 1969, p 69 8 Rosenzweig DY: Silicosis complicated by atypical mycobacterial infection. In Transactions of the 26th VA Armed Forces Pulmonary Disease Research Conference, 1967,p47 9 Bates J: A study of pulmonary disease associated with mycobacteria other than Mycobacterium tuberculodb: Clinical characteristics. Am Rev Respir Dis 96: , Snider GL, Placik B: The relationship between pulmonary tuberculosis and bronchogenic carcinoma. Am Rev Respir Dis 99: , Wolinsky E: Nontuberculous mycobacterial infections of man. Med Clin N Am 58: , 1974 PULMONARY MYCOBACTERIAL INFECnONS 118

Diagnosis and Treatment of Tuberculosis, 2011

Diagnosis and Treatment of Tuberculosis, 2011 Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is

More information

Fundamentals of Tuberculosis (TB)

Fundamentals of Tuberculosis (TB) TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported

More information

Clinical review of pulmonary disease caused by Mycobacterium xenopi

Clinical review of pulmonary disease caused by Mycobacterium xenopi Thorax 1983;38: 373-377 Clinical review of pulmonary disease caused by Mycobacterium xenopi MJ SMITH, KM CITRON From the Cardiothoracic Institute, Brompton Hospital, London ABSTRACT Mycobacterium xenopi

More information

Treatment of Tuberculosis, 2017

Treatment of Tuberculosis, 2017 Treatment of Tuberculosis, 2017 Charles L. Daley, MD National Jewish Health University of Colorado Health Sciences Center Treatment of Tuberculosis Disclosures Advisory Board Horizon, Johnson and Johnson,

More information

Chapter 22. Pulmonary Infections

Chapter 22. Pulmonary Infections Chapter 22 Pulmonary Infections Objectives State the incidence of pneumonia in the United States and its economic impact. Discuss the current classification scheme for pneumonia and be able to define hospital-acquired

More information

TUBERCULOSIS. Pathogenesis and Transmission

TUBERCULOSIS. Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission Infection to Disease Diagnostic & Isolation Updates Treatment Updates Pathogenesis Droplet nuclei of 5µm or less are

More information

1 n 1965, Fuchs 1 reported a study of 3,200 Veterans

1 n 1965, Fuchs 1 reported a study of 3,200 Veterans Prophylaxis with in Inactive Tuberculosis* A Veterans Administration Cooperative Study XII Abraham Falk, M.D., and George F. Fuchs, M.D., F.C.C.P. Based on a study indicating a significant rate of reactivation

More information

DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE

DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH Assistant Professor University of Texas Health Science Center Staff Physician, Texas Center for Infectious Diseases TB Nurse Case

More information

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition Pulmonary Tuberculosis Debra Mercer BSN, RN, RRT Definition Tuberculosis is a contagious bacterial infection of the lungs caused by Mycobacterium Tuberculosis (TB) Etiological Agent: Mycobacterium Tuberculosis

More information

Nontuberculous Mycobacterial Lung Disease

Nontuberculous Mycobacterial Lung Disease Non-TB Mycobacterial Disease Jeffrey P. Kanne, MD Nontuberculous Mycobacterial Lung Disease Jeffrey P. Kanne, M.D. Consultant Disclosures Perceptive Informatics Royalties (book author) Amirsys, Inc. Wolters

More information

Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017

Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following disclosures

More information

Diagnosis and Medical Management of Latent TB Infection

Diagnosis and Medical Management of Latent TB Infection Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,

More information

Tuberculosis Tools: A Clinical Update

Tuberculosis Tools: A Clinical Update Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary

More information

Clarithromycin-resistant Mycobacterium Shinjukuense Lung Disease: Case Report and Literature Review

Clarithromycin-resistant Mycobacterium Shinjukuense Lung Disease: Case Report and Literature Review Showa Univ J Med Sci 28 4, 373 377, December 2016 Case Report Clarithromycin-resistant Mycobacterium Shinjukuense Lung Disease: Case Report and Literature Review Makoto HAYASHI 1, Satoshi MATSUKURA 1,

More information

Shortened Survival of Lung Cancer Patients Initially Presenting with Pulmonary Tuberculosis

Shortened Survival of Lung Cancer Patients Initially Presenting with Pulmonary Tuberculosis Shortened Survival of Lung Cancer Patients Initially Presenting with Pulmonary Tuberculosis Yuh-Min Chen, Jing-Yi Chao, Chun-Ming Tsai, Pui-Yuen Lee and Reury-Perng Perng 'Chest Department and Cancer Therapy

More information

Errors in Dx and Rx of TB

Errors in Dx and Rx of TB Errors in Dx and Rx of TB David Schlossberg, MD, FACP Professor of Medicine Temple University School of Medicine Medical Director, TB Control Program Philadelphia Department of Public Health TB Still a

More information

Treatment of Tuberculosis

Treatment of Tuberculosis Recommendations and Reports June 20, 2003 / 52(RR11);1-77 Recommendations and Reports June 20, 2003 / 52(RR11);1-77 Treatment of Tuberculosis American Thoracic Society, CDC, and Infectious Diseases Society

More information

Treatment of Tuberculosis

Treatment of Tuberculosis Treatment of Tuberculosis American Thoracic Society, CDC, and Infectious Diseases Society of America Please note: An erratum has been published for this article. To view the erratum, please click here.

More information

Appendix C. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997)

Appendix C. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997) Appendix C Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997) Since publication of the Recommendations for Counting Reported Tuberculosis Cases 1 in January 1977, numerous changes

More information

(13) "Pulmonary tuberculosis" means tuberculosis that affects the lungs.

(13) Pulmonary tuberculosis means tuberculosis that affects the lungs. ACTION: Withdraw Final DATE: 12/06/2005 8:17 AM 5122-3-09 Integrated behavioral healthcare system (IBHS) tuberculosis control program. (A) The purpose of this rule shall be to establish a policy that will

More information

has the following disclosures to make:

has the following disclosures to make: CLINICAL DIAGNOSIS AND MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH September 22, 2015 TB Nurse Case Management September 22 24, 2015 San Antonio. TX EXCELLENCE EXPERTISE INNOVATION Annie Kizilbash

More information

Diagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015

Diagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015 Diagnosis & Medical Case Management of TB Disease Lisa Armitige, MD, PhD October 22, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE

More information

Characteristics of Mycobacterium

Characteristics of Mycobacterium Mycobacterium Characteristics of Mycobacterium Very thin, rod shape. Culture: Aerobic, need high levels of oxygen to grow. Very slow in grow compared to other bacteria (colonies may be visible in up to

More information

Appendix B. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997)

Appendix B. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997) Appendix B Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997) Since publication of the Recommendations for Counting Reported Tuberculosis Cases 1 in January 1977, numerous changes

More information

Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis.

Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis. Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis. Principal Investigator: Dick Menzies, MD Evidence base for treatment of INH resistant

More information

Appendix B. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997)

Appendix B. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997) Appendix B Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997) Since publication of the Recommendations for Counting Reported Tuberculosis Cases 1 in January 1977, numerous changes

More information

Communicable Disease Control Manual Chapter 4: Tuberculosis

Communicable Disease Control Manual Chapter 4: Tuberculosis Provincial TB Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 www.bccdc.ca Communicable Disease Control Manual Definitions Page 1 2.0 DEFINITIONS Many of the definitions that follow are taken from

More information

Nontuberculous Mycobacteria (NTM) in Patients with Cystic Fibrosis

Nontuberculous Mycobacteria (NTM) in Patients with Cystic Fibrosis Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/cystic-fibrosis-in-focus/nontuberculous-mycobacteria-ntm-in-patientswith-cystic-fibrosis/8337/

More information

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No

More information

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict

More information

The authors assessed drug susceptibility patterns

The authors assessed drug susceptibility patterns Drug Resistance Among Tuberculosis Patients, 1991 and 1992 New York City, CYNTHIA R. DRIVER, RN, MPH THOMAS R. FRIEDEN, MD, MPH ALAN B. BLOCH, MD, MPH IDA M. ONORATO, MD All the authors are with the Division

More information

TREATMENT OF PULMONARY TUBERCULOSIS BY THORA- COPLASTY IN PATIENTS OVER 50 YEARS OF AGE

TREATMENT OF PULMONARY TUBERCULOSIS BY THORA- COPLASTY IN PATIENTS OVER 50 YEARS OF AGE Thorax (1954), 9, 2 1. TREATMENT OF PULMONARY TUBERCULOSIS BY THORA- COPLASTY IN PATIENTS OVER 50 YEARS OF AGE BY PETER BEACONSFIELD, H. S. COULTHARD, AND F. G. KERGIN From the Toronto Hospital for the

More information

TB Intensive San Antonio, Texas

TB Intensive San Antonio, Texas TB Intensive San Antonio, Texas April 6-8, 2011 TB Disease: ATS/CDC/IDSA Guidelines Barbara Seaworth, MD Thursday April 7, 2011 Barbara Seaworth, MD has the following disclosures to make: Has received

More information

Treatment of Active Tuberculosis

Treatment of Active Tuberculosis Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest

More information

Six-month Therapy with Aerosolized Interferon-γfor Refractory Multidrug-Resistant Pulmonary Tuberculosis

Six-month Therapy with Aerosolized Interferon-γfor Refractory Multidrug-Resistant Pulmonary Tuberculosis J Korean Med Sci 2004; 19: 167-71 ISSN 1011-8934 Copyright The Korean Academy of Medical Sciences Six-month Therapy with Aerosolized Interferon-γfor Refractory Multidrug-Resistant Pulmonary Tuberculosis

More information

Surgery for MDR/XDR Tuberculosis

Surgery for MDR/XDR Tuberculosis Surgery for MDR/XDR Tuberculosis John D. Mitchell, M.D. Davis Endowed Chair in Thoracic Surgery Professor and Chief, General Thoracic Surgery Department of Surgery University of Colorado School of Medicine

More information

TB Clinical Guidelines: Revision Highlights March 2014

TB Clinical Guidelines: Revision Highlights March 2014 TB Clinical Guidelines: Revision Highlights March 2014 AIR TRAVEL & TB CONTROL With respect to non-ambulance air travel of patients diagnosed with or suspected as having active Mycobacterium tuberculosis,

More information

Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011

Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011 TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011 Lisa Armitige, MD, PhD has the following disclosures to make:

More information

Managing Complex TB Cases Diana M. Nilsen, MD, RN

Managing Complex TB Cases Diana M. Nilsen, MD, RN Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private

More information

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening

More information

Tuberculosis Intensive

Tuberculosis Intensive Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 Tuberculosis Pathogenesis Lynn Horvath, MD April 3, 2012 Lynn Horvath, MD has the following disclosures to make: No conflict of interests No relevant

More information

PLASMA COPPER AND ZINC LEVELS IN PULMONARY TUBERCULOSIS

PLASMA COPPER AND ZINC LEVELS IN PULMONARY TUBERCULOSIS PLASMA COPPER AND ZINC LEVELS IN PULMONARY TUBERCULOSIS B.K. KHANNA, R. KUMAR, P.K. MUKERJI,* A.R. CHOWDHURY AND V,P. KAMBOJ** Summary : A study of plasma copper and zinc level was conducted in 46 normal

More information

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection? Those oral antibiotics are just not working! Inpatient Standards of Care & Discharge Planning S/He s in the Hospital: Now What Do I Do? Dana G. Kissner, MD TB Intensive Workshop, Lansing, MI 2012 Objectives:

More information

Treatment of Tuberculosis

Treatment of Tuberculosis TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features

More information

HEALTH SERVICES POLICY & PROCEDURE MANUAL

HEALTH SERVICES POLICY & PROCEDURE MANUAL PAGE 1 of 12 PURPOSE To provide guidelines for the prevention and the treatment of tuberculosis (TB) in the N.C. Department of Correction. POLICY The N. C. Department of Correction will abide by this Tuberculosis

More information

CHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

CHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY CHAPTER:1 TUBERCULOSIS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY GLOBAL EMERGENCY: * Tuberculosis kills 5,000 people a day! * 2.3 million die each year!

More information

TB Program Management San Antonio, Texas November 5-7, 2008

TB Program Management San Antonio, Texas November 5-7, 2008 TB Program Management San Antonio, Texas November 5-7, 2008 Infection Control Lynelle Phillips, RN, MPH November 7, 2008 Infection Control Lynelle Phillips, RN MPH Nurse Consultant Heartland National TB

More information

Weekly. August 8, 2003 / 52(31);

Weekly. August 8, 2003 / 52(31); Weekly August 8, 2003 / 52(31);735-739 Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis

More information

Tuberculosis - clinical forms. Dr. A.Torossian,, M.D., Ph. D. Department of Respiratory Diseases

Tuberculosis - clinical forms. Dr. A.Torossian,, M.D., Ph. D. Department of Respiratory Diseases Tuberculosis - clinical forms Dr. A.Torossian,, M.D., Ph. D. Department of Respiratory Diseases 1 TB DISEASE Primary Post-primary (Secondary) Common primary forms Primary complex Tuberculosis of the intrathoracic

More information

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interest.

More information

CHAPTER 3: DEFINITION OF TERMS

CHAPTER 3: DEFINITION OF TERMS CHAPTER 3: DEFINITION OF TERMS NOTE: TB bacteria is used in place of Mycobacterium tuberculosis and Mycobacterium tuberculosis complex in most of the definitions presented here. 3.1 Acid-fast bacteria

More information

2016 Annual Tuberculosis Report For Fresno County

2016 Annual Tuberculosis Report For Fresno County 206 Annual Tuberculosis Report For Fresno County Cases Rate per 00,000 people 206 Tuberculosis Annual Report Fresno County Department of Public Health (FCDPH) Tuberculosis Control Program Tuberculosis

More information

Diagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015

Diagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015 Diagnosis and Medical Management of TB Disease Quratulian Annie Kizilbash, MD, MPH March 17, 2015 TB Nurse Case Management March 17 19, 2015 San Antonio, Texas EXCELLENCE EXPERTISE INNOVATION Quratulian

More information

11/3/2009 SECOND EDITION Madhukar Pai McGill University. ISTC Training Modules Introduction

11/3/2009 SECOND EDITION Madhukar Pai McGill University. ISTC Training Modules Introduction SECOND EDITION 2009 Madhukar Pai McGill University Introduction 1 Purpose of ISTC ISTC Version 2: Key Points 21 Standards Differ from existing guidelines: standards present what should be done, whereas,

More information

ACTIVE TUBERCULOSIS IN MACOMB COUNTY, A Review of TB Program Data,

ACTIVE TUBERCULOSIS IN MACOMB COUNTY, A Review of TB Program Data, ACTIVE TUBERCULOSIS IN MACOMB COUNTY, 1996-2010 A Review of TB Program Data, 1996-2010 Prepared by: Janice M. Chang, MBBS, MPH Division Director, Health Promotion and Disease Control Macomb County Health

More information

Yakima Health District BULLETIN

Yakima Health District BULLETIN Yakima Health District BULLETIN Summary Volume 13, Issue 1 February, 2014 Tuberculosis in Yakima County The rate of active tuberculosis (TB) in Yakima County has declined by about two-thirds over the past

More information

Annual Tuberculosis Report Oregon 2007

Annual Tuberculosis Report Oregon 2007 Annual Tuberculosis Report Oregon 7 Oregon Department of Human Services Public Health Division TB Program April 8 Page 2 Table of Contents Charts Chart 1 TB Incidence in the US and Oregon, 1985-7.. page

More information

Tuberculosis Intensive November 17 20, 2015 San Antonio, TX

Tuberculosis Intensive November 17 20, 2015 San Antonio, TX Treatment of Tuberculosis Elizabeth S. Guy, MD November 17, 2015 Tuberculosis Intensive November 17 20, 2015 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Elizabeth S. Guy, MD has the following disclosures

More information

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either

More information

Mycobacterium szulgai: a rare pathogen. Description of the first pulmonary case reported in Argentina ACCEPTED

Mycobacterium szulgai: a rare pathogen. Description of the first pulmonary case reported in Argentina ACCEPTED JCM Accepts, published online ahead of print on 27 June 2007 J. Clin. Microbiol. doi:10.1128/jcm.00148-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights

More information

TB the basics. (Dr) Margaret (DHA) and John (INZ)

TB the basics. (Dr) Margaret (DHA) and John (INZ) TB the basics (Dr) Margaret (DHA) and John (INZ) Question 1 The scientist who discovered M. tuberculosis was: A: Louis Pasteur B: Robert Koch C: Jean-Antoine Villemin D: Calmette and Guerin Question 2

More information

Tuberculosis Pathogenesis

Tuberculosis Pathogenesis Tuberculosis Pathogenesis Renuka Khurana, MD, MPH May 12, 2015 TB for Community Providers May 12, 2015 Phoenix, Arizona EXCELLENCE EXPERTISE INNOVATION Renuka Khurana, MD, MPH has the following disclosures

More information

TB and Comorbidities Adriana Vasquez, MD April 12, 2018

TB and Comorbidities Adriana Vasquez, MD April 12, 2018 TB and Comorbidities Adriana Vasquez, MD April 12, 2018 TB Nurse Case Management April 10 12, 2018 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Adriana Vasquez, MD has the following disclosures to make:

More information

Bronchogenic Carcinoma

Bronchogenic Carcinoma A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most

More information

Tuberculosis (TB) Fundamentals for School Nurses

Tuberculosis (TB) Fundamentals for School Nurses Tuberculosis (TB) Fundamentals for School Nurses June 9, 2015 Kristin Gall, RN, MSN/Pat Infield, RN-TB Program Manager Marsha Carlson, RN, BSN Two Rivers Public Health Department Nebraska Department of

More information

Contact Investigation

Contact Investigation Tuberculosis Ann Raftery, RN, PHN, MSc GHS Learning Objectives Upon completion of this session, participants will be able to: Describe the criteria used and method for determining the infectious period

More information

HISTOPLASMOSIS (RECEIVED FOR PUBLICATION APRIL 6, 1960) was not confirmed by culture. This patient was in

HISTOPLASMOSIS (RECEIVED FOR PUBLICATION APRIL 6, 1960) was not confirmed by culture. This patient was in Thorax (1960), 15, 204. A REPORT OF 12 SELECTED CASES OF PULMONARY HISTOPLASMOSIS BY ALEX SALIBA AND OREN A. BEATTY From District Two State Tuberculosis Hospital, Louisville, Kentucky, U.S.A. (RECEIVED

More information

Mycobacterium tuberculosis

Mycobacterium tuberculosis Mycobacterium tuberculosis Mycobacterium tuberculosis Ø small, aerobic, nonmotile bacteria Ø Gram-positive bacillus Ø can survive in a dry state for weeks Ø grow only within the cells of a host organism

More information

I. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES. Male % Female %

I. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES. Male % Female % San Joaquin County (SJC) in 03, (N=43) County Rate = 6. Cases per 00,000 Population I. Demographic Information Table I-A: TB cases by gender, SJC, 03 (N=43) GENDER NUMBER OF CASES Male 6 60.5% Female 7

More information

Summary Statistics of Reported and Verified Cases of Tuberculosis in San Joaquin County in 2012, (N=44) County Rate = 6.3 Cases per 100,000 Population

Summary Statistics of Reported and Verified Cases of Tuberculosis in San Joaquin County in 2012, (N=44) County Rate = 6.3 Cases per 100,000 Population I. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES Male 29 65.9% Female 15 34.1% AGE GROUP NUMBER OF CASES PERCENT OF CASES 04 3 6.8% 514 2 4.5% 1524 3 6.8% 2544 6 13.6% 4564 15 34.1% 65+

More information

Key words: azithromycin; bronchiectasis; clarithromycin; clofazimine; ethambutol; Mycobacterium avium

Key words: azithromycin; bronchiectasis; clarithromycin; clofazimine; ethambutol; Mycobacterium avium Treatment of Mycobacterium aviumintracellulare complex Lung Disease With a Macrolide, Ethambutol, and Clofazimine* Stephen K. Field, MD, CM, FCCP; Robert L. Cowie, MD, MSc Background: Mycobacterium avium-intracellulare

More information

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012 TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release

More information

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

TB Nurse Case Management San Antonio, Texas July 18 20, 2012 TB Nurse Case Management San Antonio, Texas July 18 20, 2012 Pediatric TB Kim Smith, MD, MPH July 19, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests No relevant

More information

Tuberculosis. By: Shefaa Q aqa

Tuberculosis. By: Shefaa Q aqa Tuberculosis By: Shefaa Q aqa Tuberculosis is a communicable chronic granulomatous disease caused by Mycobacterium tuberculosis. It usually involves the lungs but may affect any organ or tissue in the

More information

TB BASICS: PRIORITIES AND CLASSIFICATIONS

TB BASICS: PRIORITIES AND CLASSIFICATIONS TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE MAY 8-11, 2018 TB BASICS: PRIORITIES AND CLASSIFICATIONS LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1. List

More information

TB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009

TB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009 TB Intensive Houston, Texas November 10-12, 12 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 1 OUTLINE Stages

More information

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed

More information

Profile of Tuberculosis Infection among Current HIV+ Patients at the Philippine General Hospital

Profile of Tuberculosis Infection among Current HIV+ Patients at the Philippine General Hospital Profile of Tuberculosis Infection among Current HIV+ Patients at the Albert B. Albay Jr., MD Jemylyn Garcia, MD Joel Santiaguel, MD UP- TB in the Philippines 6 th leading cause of morbidity and mortality

More information

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Microbiology Epidemiology Common disease presentations Diagnosis of active

More information

TB BASICS: PRIORITIES AND CLASSIFICATIONS

TB BASICS: PRIORITIES AND CLASSIFICATIONS TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE NOVEMBER 1-4, 2016 TB BASICS: PRIORITIES AND CLASSIFICATIONS LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1.

More information

BACTERIOLOGICAL AND EPIDEMIOLOGICAL

BACTERIOLOGICAL AND EPIDEMIOLOGICAL Recently atypical acid-fast bacillli have been increasingly reported in diagnostic microbiology. The ultimate classification and significance of these organisms is still to be determined. This report presents

More information

Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers

Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers Who Should Be Screened for Latent Tuberculosis Infection (LTBI)?... 2 What tests are used to screen for LTBI?... 2 How

More information

TB Intensive San Antonio, Texas August 7-10, 2012

TB Intensive San Antonio, Texas August 7-10, 2012 TB Intensive San Antonio, Texas August 7-10, 2012 Nontuberculosis Mycobacterial Lung Disease David Griffith, MD August 8, 2012 David Griffith, MD has the following disclosures to make: No conflict of interests

More information

TB in the Patient with HIV

TB in the Patient with HIV TB in the Patient with HIV Lisa Y. Armitige, MD, PhD May 11, 2017 TB Intensive May 9 12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD, has the following disclosures to

More information

CLINICAL DIAGNOSIS AND MANAGEMENT OF TB Disease

CLINICAL DIAGNOSIS AND MANAGEMENT OF TB Disease CLINICAL DIAGNOSIS AND MANAGEMENT OF TB Disease Barbara J Seaworth MD Medical Director Heartland National TB Center Professor of Medicine University of Texas Health Center Tyler Barbara J Seaworth MD has

More information

SHORT COURSE CHEMOTHERAPY FOR PULMONARY TUBERCULOSIS IN CHILDREN

SHORT COURSE CHEMOTHERAPY FOR PULMONARY TUBERCULOSIS IN CHILDREN SHORT COURSE CHEMOTHERAPY FOR PULMONARY TUBERCULOSIS IN CHILDREN Padma Ramachandran, A.S. Kripasankar and M. Duraipandian* chest radiograph suggestive of tuberculosis. There are a number of reports on

More information

TB Contact Investigation Basics

TB Contact Investigation Basics TB Nurse Case Management Lisle, Illinois April 27-28, 28 2010 TB Contact Investigation Basics Carrie Storrs, RN April 28, 2010 Contact Investigation Carrie Storrs TB Program Illinois Department of Public

More information

Nontuberculous Mycobacteria (NTM)

Nontuberculous Mycobacteria (NTM) Nontuberculous Mycobacteria (NTM) Bacteria, like plants and animals, have been classified into similar groups. The groups are called "families." One such family of bacteria is known as the Mycobacteriaceae.

More information

Tuberculosis in Chicago 2007

Tuberculosis in Chicago 2007 City of Chicago Communicable Disease Information Department of Public Health Richard M. Daley, Mayor May 2008 Terry Mason, MD, FACS, Commissioner www.cityofchicago.org/health/ West Side Center For Disease

More information

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016 Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the

More information

Transmission and Pathogenesis of Tuberculosis

Transmission and Pathogenesis of Tuberculosis Transmission and Pathogenesis of Tuberculosis Adithya Cattamanchi MD, MAS Associate Professor of Medicine University of California San Francisco Slides adapted from James Watts, Phil Hopewell Transmission

More information

Tuberculosis Populations at Risk

Tuberculosis Populations at Risk Tuberculosis Populations at Risk One-third of the world is infected with TB, an average of one new infection per second Two million people died from tuberculosis in 2010, 1 every 20 seconds TB is the leading

More information

Role of Sugery in treatment of patient with MDR/XDR pulmonary TB - Experience from Georgia

Role of Sugery in treatment of patient with MDR/XDR pulmonary TB - Experience from Georgia Role of Sugery in treatment of patient with MDR/XDR pulmonary TB - Experience from Georgia Sergo Vashakidze, MD, PhD Coordinator of Surgical Works at the National Center for Tuberculosis and Lung Diseases,

More information

Postgraduate Course ERS Glasgow 2004 Surgical approach to multiresistant cavitary mycobacteriosis

Postgraduate Course ERS Glasgow 2004 Surgical approach to multiresistant cavitary mycobacteriosis REVIEW Postgraduate Course ERS Glasgow 2004 Surgical approach to multiresistant cavitary mycobacteriosis Educational aims To explain the present importance of surgery in TB management. To describe the

More information

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,

More information

RADIOLOGIC EVALUATION OF PULMONARY NTM INFECTION. Tilman Koelsch, MD National Jewish Health - Department of Radiology

RADIOLOGIC EVALUATION OF PULMONARY NTM INFECTION. Tilman Koelsch, MD National Jewish Health - Department of Radiology Pr N op ot er fo ty r R of ep Pr ro es du en ct te io r n RADIOLOGIC EVALUATION OF PULMONARY NTM INFECTION Tilman Koelsch, MD National Jewish Health - Department of Radiology Disclosures No relevant financial

More information

The Role of Rifampin for the Treatment of Latent TB Infection. Introduction. Introduction

The Role of Rifampin for the Treatment of Latent TB Infection. Introduction. Introduction The Role of Rifampin for the Treatment of Latent TB Infection March 26, 2008 Alfred A. Lardizabal, MD Associate Professor of Medicine New Jersey Medical School Global Tuberculosis institute Treatment of

More information

Treatment of Tuberculosis

Treatment of Tuberculosis Treatment of Tuberculosis Marcos Burgos, MD April 5, 2016 TB Intensive April 5 8, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures to make: No conflict

More information